Finance

Lists
ABOS:NASDAQ
Acumen Pharmaceuticals Inc
$2.83
+3.28%
(+0.090) 1D
Aug 19, 9:56:24 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABOS...
Open
$2.79
High
$2.85
Low
$2.79
Mkt. cap
205.45M
Avg. vol.
355.72K
Volume
62.19K
52-wk high
$3.60
52-wk low
$1.21
EPS
-$1.63
Beta
0.36
Shares outstanding
72.32M
No. of employees
60
Open
$2.79
High
$2.85
Low
$2.79
Mkt. cap
205.45M
Avg. vol.
355.72K
Volume
62.19K
52-wk high
$3.60
52-wk low
$1.21
EPS
-$1.63
Beta
0.36
Shares outstanding
72.32M
No. of employees
60
News stories
From web sources and news partners
About Acumen Pharmaceuticals Inc
CEO-
Employees60
FoundedJan 1, 1996
HeadquartersNewton, Massachusetts, United States
SectorBiotechnology
Websiteacumenpharm.com
Analyst ratings
Based on 2 analysts giving stock ratings to ABOS in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for ABOS in the last 3 months.
Highest
Current $2.83
$8.00 (+182.69%)
Average
$6.00 (+112.01%)
Lowest
$4.00 (+41.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Geoff Meacham
Citi
Buy
Maintained
$4.00
+41.3%
08/13/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$8.00
+182.7%
06/11/2026
Thomas Shrader
BTIG
Buy
Maintained
$8.00
+182.7%
04/02/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.45 / -$0.41
-11.02%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
21.97M
20.53M
16.48M
27.81M
Cost of revenue
21.97M
20.53M
16.48M
27.81M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.54M
4.67M
4.66M
4.75M
Operating expense
4.54M
4.67M
4.66M
4.75M
Total operating expenses
26.51M
25.20M
21.15M
32.56M
Operating income
-26.51M
-25.20M
-21.15M
-32.56M
Other non operating income
-509.00K
-174.00K
417.00K
-179.00K
EBT including unusual items
-26.45M
-25.14M
-20.74M
-32.72M
EBT excluding unusual items
-26.45M
-25.14M
-20.74M
-32.72M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.45M
-25.14M
-20.74M
-32.72M
Net profit margin
-
-
-
-
Earnings per share
-0.44
-0.41
-0.33
-0.45
Interest and investment income
1.64M
1.32M
1.06M
1.11M
Interest expense
-1.07M
-1.09M
-1.07M
-1.09M
Net interest expenses
571.00K
235.00K
-5.00K
17.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.50M
-25.19M
-21.14M
-32.54M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps